Latest News-Kaixing Life Technology (Shanghai) Co., LTD Mediaroom_Page

CARsgen Announced 2022 Annual Results and Business Updates

SHANGHAI, March 22, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK...

2023-03-22 20:50 2192

CARsgen Announced 2022 Annual Results and Business Updates

CARsgen Announces Collaboration Agreement to Evaluate AB011 in Combination with PD-L1 Checkpoint Inhibitor to Treat Gastric Cancer

SHANGHAI, Jan. 31, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK)...

2023-01-31 21:50 3087

CARsgen Presents Results on Anti-Claudin18.2-mAb AB011 at ASCO GI

SHANGHAI, Jan. 20, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK)...

2023-01-20 21:50 4609

CARsgen Therapeutics and Huadong Medicine Announce Collaboration Agreement For Zevorcabtagene Autoleucel In Mainland China

SHANGHAI, Jan. 16, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (2171.HK), a company ...

2023-01-16 18:00 2420

CARsgen Presents Data from China Pivotal Phase II Trial of BCMA CAR T Zevor-cel (CT053) at 2022 ASH Annual Meeting

SHANGHAI, Dec. 12, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK)...

2022-12-12 21:50 2242

CARsgen Appoints Dr. Sylvie Peltier as Senior Vice President of Global Regulatory Affairs

SHANGHAI, Oct. 31, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK)...

2022-10-31 21:30 2707

CARsgen Appoints Dr. Sylvie Peltier as Senior Vice President of Global Regulatory Affairs

CARsgen Announces NDA Acceptance of BCMA CAR T Zevor-cel (CT053) by China NMPA

SHANGHAI, Oct. 18, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK)...

2022-10-18 20:50 2491

CARsgen 2022 Interim Results: Innovative CAR T-cell Technologies and Robust Pipeline

SHANGHAI, Aug. 24, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK)...

2022-08-24 20:50 2797

CARsgen 2022 Interim Results: Innovative CAR T-cell Technologies and Robust Pipeline

Case Report of Long Term Complete Response in Hepatocellular Carcinoma to CARsgen's GPC3 CAR T Cells (CT011) Published in Frontiers in Immunology

SHANGHAI, Aug. 18, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK)...

2022-08-18 20:50 1848

Case Report of Long Term Complete Response in Hepatocellular Carcinoma to CARsgen's GPC3 CAR T Cells (CT011) Published in Frontiers in Immunology

CARsgen Appoints Dr. Hua Jiang as Executive Director

SHANGHAI, Aug. 2, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK),...

2022-08-02 20:50 2150

CARsgen Appoints Dr. Hua Jiang as Executive Director

CARsgen Therapeutics Presents Updated Data for CT041 Claudin18.2 CAR T-cells in Solid Tumors at ASCO 2022

SHANGHAI, June 6, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK),...

2022-06-06 20:50 2920

Nature Medicine Publishes Results from an Investigator-Initiated Trial of CARsgen's CT041 Claudin18.2 CAR T Cells in Gastrointestinal Cancers

SHANGHAI, May 10, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK),...

2022-05-10 20:50 1906

CARsgen Appoints Dr. Raffaele Baffa as Chief Medical Officer

SHANGHAI and BOSTON, April 7, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Cod...

2022-04-07 23:42 2450

CARsgen Appoints Dr. Raffaele Baffa as Chief Medical Officer

CARsgen Announces First Patient Enrollment in the Confirmatory Phase II Clinical Trial of CT041 in China

SHANGHAI, March 23, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK...

2022-03-23 20:50 1669

CARsgen Announces First Patient Enrollment in the Confirmatory Phase II Clinical Trial of CT041 in China

CARsgen 2021 Annual Results: Steady Advancement in Innovative CAR T Products and Technologies

SHANGHAI, March 23, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK...

2022-03-23 20:50 3256

CARsgen 2021 Annual Results: Steady Advancement in Innovative CAR T Products and Technologies

Claudin18.2 CAR T Cells (CT041) Receives Approval to Initiate A Confirmatory Phase II Clinical Trial for advanced GC/GEJ in China

SHANGHAI, March 3, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK)...

2022-03-03 21:50 2036

CARsgen Appoints Richard John Daly as the President of CARsgen Therapeutics Corporation

SHANGHAI and DURHAM, N.C., Jan. 17, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Sto...

2022-01-17 21:50 2301